The Type 2 diabetes research collaboration with Novo Nordisk provides important validation for e-therapeutics and its proprietary Network-Driven Drug Discovery (NDD) platform. It is the first commercial deal to arise from the extensive business development efforts, and its significance extends beyond the undisclosed deal economics. It marks the first exploitation of the NDD platform in metabolic disease, with the world leader in diabetes, providing valuable external endorsement and derisking of the platform. It may also catalyse further near-term deals with large pharma players; multiple discussions are known to be underway with various potential partners, across a spectrum of disease areas. Our valuation is £57.8m or 21.9p/share.
10 Dec 2018
First commercial deal secured with global diabetes leader
Sign up for free to access
Get access to the latest equity research in real-time from 12 commissioned providers.
Get access to the latest equity research in real-time from 12 commissioned providers.
First commercial deal secured with global diabetes leader
e-Therapeutics plc (ETX:LON) | 9.2 0 1.7% | Mkt Cap: 53.9m
- Published:
10 Dec 2018 -
Author:
Mick Cooper PhD -
Pages:
5
The Type 2 diabetes research collaboration with Novo Nordisk provides important validation for e-therapeutics and its proprietary Network-Driven Drug Discovery (NDD) platform. It is the first commercial deal to arise from the extensive business development efforts, and its significance extends beyond the undisclosed deal economics. It marks the first exploitation of the NDD platform in metabolic disease, with the world leader in diabetes, providing valuable external endorsement and derisking of the platform. It may also catalyse further near-term deals with large pharma players; multiple discussions are known to be underway with various potential partners, across a spectrum of disease areas. Our valuation is £57.8m or 21.9p/share.